These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 35764907)
21. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274 [TBL] [Abstract][Full Text] [Related]
22. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443 [TBL] [Abstract][Full Text] [Related]
23. Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study. Nakasu Y; Mitsuya K; Hayashi N; Okamura I; Mori K; Enami T; Tatara R; Nakasu S; Ikeda T Springerplus; 2016; 5():307. PubMed ID: 27066340 [TBL] [Abstract][Full Text] [Related]
24. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329 [TBL] [Abstract][Full Text] [Related]
25. Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience. Yoshida M; Kato T; Hiu T; Imaizumi Y; Morimoto S; Niino D; Yamaguchi S; Baba S; Ujifuku K; Yoshida K; Matsuo A; Morofuji Y; Izumo T; Okano S; Miyazaki Y; Matsuo T Int J Hematol; 2023 Sep; 118(3):333-339. PubMed ID: 37393325 [TBL] [Abstract][Full Text] [Related]
26. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome. Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112 [TBL] [Abstract][Full Text] [Related]
27. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235 [TBL] [Abstract][Full Text] [Related]
28. A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine. Hattori K; Sakata-Yanagimoto M; Okoshi Y; Kato T; Kurita N; Yokoyama Y; Obara N; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Hasegawa Y; Chiba S J Clin Exp Hematop; 2017 Oct; 57(2):41-46. PubMed ID: 28781291 [TBL] [Abstract][Full Text] [Related]
29. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. Correa DD; Braun E; Kryza-Lacombe M; Ho KW; Reiner AS; Panageas KS; Yahalom J; Sauter CS; Abrey LE; DeAngelis LM; Omuro A J Neurooncol; 2019 Sep; 144(3):553-562. PubMed ID: 31377920 [TBL] [Abstract][Full Text] [Related]
30. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma. Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782 [TBL] [Abstract][Full Text] [Related]
31. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857 [TBL] [Abstract][Full Text] [Related]
32. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989 [TBL] [Abstract][Full Text] [Related]
34. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy. Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065 [TBL] [Abstract][Full Text] [Related]
35. The role of additional radiotherapy for primary central nervous system lymphoma. Zacher J; Kasenda B; Engert A; Skoetz N Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009211. PubMed ID: 24931518 [TBL] [Abstract][Full Text] [Related]
36. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380 [TBL] [Abstract][Full Text] [Related]
37. Challenges and opportunities in primary CNS lymphoma: A systematic review. Kerbauy MN; Moraes FY; Lok BH; Ma J; Kerbauy LN; Spratt DE; Santos FP; Perini GF; Berlin A; Chung C; Hamerschlak N; Yahalom J Radiother Oncol; 2017 Mar; 122(3):352-361. PubMed ID: 28104300 [TBL] [Abstract][Full Text] [Related]
38. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia. Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325 [TBL] [Abstract][Full Text] [Related]
39. Consolidation Treatment for Primary Central Nervous System Lymphoma: Which Modality for Whom? Bairey O; Shargian-Alon L; Siegal T Acta Haematol; 2021; 144(4):389-402. PubMed ID: 33242855 [TBL] [Abstract][Full Text] [Related]
40. Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience. Khurana A; Micallef IN; LaPlant BR; Patrick O'Neill B; Habermann TM; Ansell SM; Inwards DJ; Porrata LF; Paludo J; Bisneto JCV; Johnston PB Biol Blood Marrow Transplant; 2020 Dec; 26(12):2217-2222. PubMed ID: 32818553 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]